Mirum Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines for rare and orphan diseases, particularly cholestatic liver diseases, viral hepatitis, and rare neurological conditions. The company operates a portfolio of FDA-approved medicines including Livmarli for cholestatic pruritus in genetic cholestatic diseases, Cholbam for bile acid synthesis disorders, and Ctexli for cerebrotendinous xanthomatosis, which it sells through specialized sales forces in North America and select European markets while pursuing international expansion through partnerships and licensing agreements. The company also maintains a clinical-stage pipeline of candidates, including volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for chronic hepatitis D, and MRM-3379 for fragile X syndrome, and generates revenue through direct pharmaceutical sales, royalties and milestone payments from licensed distributors, and periodic strategic acquisitions of complementary rare disease assets.